UnknownPHASE2, PHASE3NCT01635803

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Principal Investigator
Reinier O Schlingemann, MD, PhD
Academic Medical Center, Dept. Ophthalmology, Room A2-122, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Intervention
Bevacizumab(drug)
Enrollment
296 enrolled
Eligibility
18 years · All sexes
Timeline
2012

Study locations (1)

Collaborators

Leiden University Medical Center · Universitair Ziekenhuis Brussel · Erasmus Medical Center · Radboud University Medical Center · UMC Utrecht · University Medical Center Groningen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01635803 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials